PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35450359-0 2022 Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors. Glutathione 12-15 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 69-73 33910646-13 2021 In contrast, in lower-grade astrocytoma, mainly in those harboring the IDH1 mutation, the gene expression profile indicates that tumor cells might be sensitized to oxidative stress due to reduced GSH synthesis. Glutathione 196-199 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 71-75 33115694-0 2020 GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo. Glutathione 0-3 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 26-30 33115694-4 2020 This study aims to examine GABA and GSH alterations in IDH1-mutated low-grade gliomas using HERMES. Glutathione 36-39 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 55-59 33115694-15 2020 Our results suggest that HERMES is a reliable tool to simultaneously measure GABA and GSH alterations in low-grade gliomas with IDH1 mutations. Glutathione 86-89 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 128-132 32729927-1 2020 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversible NADP+-dependent conversion of isocitrate to alpha-ketoglutarate (alphaKG) to provide critical cytosolic substrates and drive NADPH-dependent reactions like lipid biosynthesis and glutathione regeneration. Glutathione 238-249 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-26 32729927-1 2020 Isocitrate dehydrogenase 1 (IDH1) catalyzes the reversible NADP+-dependent conversion of isocitrate to alpha-ketoglutarate (alphaKG) to provide critical cytosolic substrates and drive NADPH-dependent reactions like lipid biosynthesis and glutathione regeneration. Glutathione 238-249 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 28-32 32709039-9 2020 Finally, the method was applied to the determination of changes in the GSH/GSSG ratio either in response to oxidative stress in cells lacking one or both monocarboxylate transporters MCT1 and MCT4, or in adaptation to the NADPH (nicotinamide adenine dinucleotide phosphate) consuming production of D-2-hydroxyglutarate in cells carrying mutations in the isocitrate dehydrogenase genes IDH1 and IDH2. Glutathione 71-74 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 385-389 32312817-0 2020 Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Glutathione 62-73 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 22-26 32312817-2 2020 Our present study demonstrated that IDH1-mutated cells showed elevated levels of reactive oxygen species and higher demands on Nrf2-guided glutathione de novo synthesis. Glutathione 139-150 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 36-40 32312817-5 2020 Our findings highlight triptolide as a valuable therapeutic approach for IDH1-mutated malignancies by targeting the Nrf2-driven glutathione synthesis pathway. Glutathione 128-139 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 73-77 31548295-0 2020 Blockade of Glutathione Metabolism in IDH1-Mutated Glioma. Glutathione 12-23 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 38-42 31548295-4 2020 In this study, we showed that acquisition of IDH1 mutation results in the disruption of NADP+/NADPH balance and an increased demand for glutathione (GSH) metabolism. Glutathione 136-147 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 45-49 31548295-4 2020 In this study, we showed that acquisition of IDH1 mutation results in the disruption of NADP+/NADPH balance and an increased demand for glutathione (GSH) metabolism. Glutathione 149-152 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 45-49 31548295-5 2020 Moreover, the nuclear factor erythroid 2-related factor 2 (Nrf2) plays a key protective role in IDH1-mutated cells by prompting GSH synthesis and reactive oxygen species scavenging. Glutathione 128-131 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 96-100 31548295-6 2020 Pharmacologic inhibition of the Nrf2/GSH pathway via brusatol administration exhibited a potent tumor suppressive effect on IDH1-mutated cancer in vitro and in vivo Our findings highlight a possible therapeutic strategy that could be valuable for IDH1-mutated cancer treatment. Glutathione 37-40 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 124-128 31591388-6 2019 Mechanistically, mutant IDH1 reduces the protein level of the glutathione peroxidase 4 (GPX4), a key enzyme in removing lipid ROS and ferroptosis, and promotes depletion of glutathione. Glutathione 62-73 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 24-28 30857299-1 2019 Isocitrate dehydrogenases (IDH) 1 and 2 are key metabolic enzymes that generate reduced nicotinamide adenine dinucleotide phosphate (NADPH) to maintain a pool of reduced glutathione and peroxiredoxin, and produce alpha-ketoglutarate, a co-factor of numerous enzymes. Glutathione 170-181 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-39 29923039-9 2018 Glutathione, a cellular sulphydryl reductant, has a moderate affinity for Cd2+, allowing IDH to be activated with residual Cd2+, unlike dithiothreitol, which has a much higher affinity. Glutathione 0-11 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 89-92 29662077-5 2018 Importantly, inhibition of mutant IDH1 may lead to the reprogramming of tumor metabolism, suggested by simultaneous changes in glutathione, glutamine, glutamate, and lactate. Glutathione 127-138 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 34-38 29537891-4 2018 IDH1 was positively correlated with CD44 and reduced form of glutathione. Glutathione 61-72 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 29054837-10 2017 We found that genes coding for key enzymes in de novo glutathione synthesis are highly expressed in IDH-mutant gliomas and the expression of cystathionine-beta-synthase (CBS) correlates with patient survival in the oligodendroglial subtype. Glutathione 54-65 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 100-103 28564604-4 2017 On a molecular level, diminished IDH1 activity results in reduced alpha-ketoglutarate (alphaKG) and NADPH production, paralleled by deficient carbon flux from glucose or acetate into lipids, exhaustion of reduced glutathione, increased levels of reactive oxygen species (ROS), and enhanced histone methylation and differentiation marker expression. Glutathione 213-224 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 33-37 27923831-4 2017 IDH1 silencing in GBM cells reduced levels of NADPH, deoxynucleotides, and glutathione and increased their sensitivity to radiation-induced senescence. Glutathione 75-86 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 28052098-0 2017 IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. Glutathione 138-141 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 28052098-5 2017 NADP+/NADPH and GSH quantification assays were performed to evaluate effects of IDH1 R132H mutation on the production of antioxidant NADPH and GSH. Glutathione 143-146 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 80-84 28052098-8 2017 We tested the level of NADPH and GSH and demonstrated that IDH1 R132H mutant stable cells had significantly low NADPH and GSH level compared to control or IDH1 wild type stable cells. Glutathione 33-36 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 59-63 28052098-8 2017 We tested the level of NADPH and GSH and demonstrated that IDH1 R132H mutant stable cells had significantly low NADPH and GSH level compared to control or IDH1 wild type stable cells. Glutathione 122-125 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 59-63 28052098-9 2017 The reduced antioxidants (NADPH and GSH) sensitized U87MG cells with IDH R132H mutant to 5-FU treatment. Glutathione 36-39 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 69-72 26970248-7 2016 We also observed significantly reduced glutathione (GSH) levels (39%, P = 0.019), which could be similarly caused by depletion of dihydronicotinamide-adenine dinucleotide phosphate (NADPH) during this conversion in IDH mutant gliomas. Glutathione 52-55 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 215-218 25283382-0 2015 Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Glutathione 11-14 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 67-71 25283382-7 2015 The IDH1-R132H-induced higher chemosensitivity was associated with nicotine adenine disphosphonucleotide (NADPH), glutathione (GSH) depletion, and reactive oxygen species (ROS) generation. Glutathione 114-125 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 4-8 25283382-7 2015 The IDH1-R132H-induced higher chemosensitivity was associated with nicotine adenine disphosphonucleotide (NADPH), glutathione (GSH) depletion, and reactive oxygen species (ROS) generation. Glutathione 127-130 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 4-8 25283382-8 2015 Accordingly, this IDH1-R132H-induced growth inhibition was effectively abrogated by GSH in vitro and in vivo. Glutathione 84-87 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 18-22 24362902-0 2014 An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Glutathione 53-56 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 3-7 24362902-6 2014 Accordingly, our study demonstrates that using H2O2-regulated mutant IDH1 glioma cells could obviously increase the inhibition of cell growth; nevertheless, GSH had the opposite result. Glutathione 157-160 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 69-73 23801081-1 2013 Isocitrate dehydrogenase 1 (IDH1) decarboxylates isocitrate to alpha-ketoglutarate (alpha-KG) leading to generation of NADPH, which is required to regenerate reduced glutathione (GSH), the major cellular ROS scavenger. Glutathione 166-177 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-26 23801081-1 2013 Isocitrate dehydrogenase 1 (IDH1) decarboxylates isocitrate to alpha-ketoglutarate (alpha-KG) leading to generation of NADPH, which is required to regenerate reduced glutathione (GSH), the major cellular ROS scavenger. Glutathione 166-177 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 28-32 23801081-1 2013 Isocitrate dehydrogenase 1 (IDH1) decarboxylates isocitrate to alpha-ketoglutarate (alpha-KG) leading to generation of NADPH, which is required to regenerate reduced glutathione (GSH), the major cellular ROS scavenger. Glutathione 179-182 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-26 23801081-1 2013 Isocitrate dehydrogenase 1 (IDH1) decarboxylates isocitrate to alpha-ketoglutarate (alpha-KG) leading to generation of NADPH, which is required to regenerate reduced glutathione (GSH), the major cellular ROS scavenger. Glutathione 179-182 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 28-32 23801081-5 2013 Quantification of GSH under basal conditions and following treatment with the glutathione reductase inhibitor BCNU revealed significantly lower GSH levels in IDH1 R132H expressing cells and IDH1 KD cells compared to their respective controls. Glutathione 18-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 158-162 23801081-5 2013 Quantification of GSH under basal conditions and following treatment with the glutathione reductase inhibitor BCNU revealed significantly lower GSH levels in IDH1 R132H expressing cells and IDH1 KD cells compared to their respective controls. Glutathione 18-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 190-194 23801081-5 2013 Quantification of GSH under basal conditions and following treatment with the glutathione reductase inhibitor BCNU revealed significantly lower GSH levels in IDH1 R132H expressing cells and IDH1 KD cells compared to their respective controls. Glutathione 144-147 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 158-162 22015945-9 2012 Compared with wild-type tumors, those with IDH1 mutations had elevated choline (P = 0.01) and decreased glutathione (P = 0.03) on MRS. Glutathione 104-115 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 43-47 22264756-1 2012 BACKGROUND: Cytosolic NADP(+)-dependent ICDH (IDPc) has an antioxidant effect as a supplier of NADPH to the cytosol, which is needed for the production of glutathione. Glutathione 155-166 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 46-50 22264756-9 2012 IDPc siRNA-treated melanocytes demonstrated a higher intensity of DCFDA after the addition of H(2)O(2) compared with scrambled siRNA-treated melanocytes, and a lower ratio of reduced glutathione to oxidized glutathione were observed in IDPc siRNA transfected melanocytes. Glutathione 183-194 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 22264756-9 2012 IDPc siRNA-treated melanocytes demonstrated a higher intensity of DCFDA after the addition of H(2)O(2) compared with scrambled siRNA-treated melanocytes, and a lower ratio of reduced glutathione to oxidized glutathione were observed in IDPc siRNA transfected melanocytes. Glutathione 207-218 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 21289278-4 2011 Levels of amino acids, glutathione metabolites, choline derivatives, and tricarboxylic acid (TCA) cycle intermediates were altered in mutant IDH1- and IDH2-expressing cells. Glutathione 23-34 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 141-145 19291592-2 2009 This study now reports that Cys269 of IDPc is a target for S-glutathionylation and that this modification is reversed by dithiothreitol as well as enzymatically by cytosolic glutaredoxin in the presence of GSH. Glutathione 206-209 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 38-42 19106211-1 2009 Cytosolic NADP+-dependent isocitrate dehydrogenase (IDPc) synthesizes reduced NADP (NADPH), which is an essential cofactor for the generation of reduced glutathione (GSH), the most abundant and important antioxidant in mammalian cells. Glutathione 153-164 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 52-56 19106211-1 2009 Cytosolic NADP+-dependent isocitrate dehydrogenase (IDPc) synthesizes reduced NADP (NADPH), which is an essential cofactor for the generation of reduced glutathione (GSH), the most abundant and important antioxidant in mammalian cells. Glutathione 166-169 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 52-56